OTCMKTS:BCHMF Bachem (BCHMF) Stock Price, News & Analysis $91.23 0.00 (0.00%) As of 05/29/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartShort InterestBuy This Stock About Bachem Stock (OTCMKTS:BCHMF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Bachem alerts:Sign Up Key Stats Today's Range$91.23▼$91.2350-Day Range$76.65▼$94.6252-Week Range$60.51▼$94.62VolumeN/AAverage Volume696 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingModerate Buy Company Overview Bachem Holding AG is a Switzerland‐based specialty biochemical company focused on the development, manufacturing and commercialization of peptides and oligonucleotides. Serving pharmaceutical and biotechnology clients as well as academic research institutions, the company offers a broad spectrum of products ranging from custom peptide synthesis for research applications to clinical and commercial‐grade active pharmaceutical ingredients (APIs). Bachem’s expertise extends to process development, scale‐up and GMP‐compliant production, supporting projects in therapeutic areas such as oncology, metabolic disorders and infectious diseases. Founded in 1971 and headquartered in Bubendorf, Switzerland, Bachem has grown through strategic investments in production capacity and the acquisition of complementary peptide and oligonucleotide technologies. The company operates multiple manufacturing sites across Europe, North America and Asia, including facilities in Germany, the United States and Japan. These locations are equipped with quality management systems that adhere to international regulatory standards, ensuring consistent supply and traceability for both small‐scale clinical batches and large‐volume commercial orders. Bachem’s product portfolio encompasses catalog peptides for research use, custom synthesis services, gel‐phase and solution‐phase peptide synthesis platforms, and a range of oligonucleotide chemistries. The company places a strong emphasis on innovation, collaborating with contract research organizations, universities and pharmaceutical partners to advance new therapeutic modalities. With a global network of technical and commercial teams, Bachem provides end‐to‐end project support, from early discovery through late‐stage development and commercialization.AI Generated. May Contain Errors. Read More Receive BCHMF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bachem and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BCHMF Stock News HeadlinesBachem CEO Assumes Dual Role as CCO DepartsMay 5, 2026 | tipranks.comBachem AGM Backs Board Proposals and Confirms CHF 0.90 DividendApril 29, 2026 | tipranks.comI paid $5,000 to hear Elon say thisOne investor paid $5,000 to be in a private room with Elon Musk in Los Angeles - and what he heard confirmed a conviction 15 years in the making. Musk is launching a project 27 years in the making that could be his biggest move yet. One analyst believes there is a single stock positioned to benefit most - and he is giving away the name for free.May 30 at 1:00 AM | InvestorPlace (Ad)Bachem Secures CHF 500 Million Credit Facility to Drive Strategic GrowthApril 27, 2026 | tipranks.comBachem lifts profit and dividend as heavy investments expand peptide capacityMarch 12, 2026 | tipranks.comBachem Appoints Hans Van Hees as New COO to Strengthen Global OperationsAugust 20, 2025 | tipranks.comBachem Mourns the Passing of Founder Peter GroggJune 3, 2025 | tipranks.comBachem’s AGM 2025 Approves Board Proposals and DividendApril 30, 2025 | tipranks.comSee More Headlines BCHMF Stock Analysis - Frequently Asked Questions How have BCHMF shares performed this year? Bachem's stock was trading at $60.51 at the beginning of 2026. Since then, BCHMF stock has increased by 50.8% and is now trading at $91.23. How do I buy shares of Bachem? Shares of BCHMF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today5/30/2026Next Earnings (Estimated)7/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorBasic Materials Industry Chemicals Sub-IndustryN/A Current SymbolOTCMKTS:BCHMF CIKN/A Webwww.bachem.com Phone41-58-595-2021FaxN/AEmployees2,006Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (OTCMKTS:BCHMF) was last updated on 5/30/2026 by MarketBeat.com Staff. From Our PartnersLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredPresident Trump just sparked a stock market MELT UPThe real reason Musk, Huang, Cook, and Fink just flew to Beijing Last week, the CEOs of Nvidia, Apple, Spac...Stansberry Research | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredSkip the Line Opportunity: The SpaceX IPOFormer tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...Brownstone Research | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bachem Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Bachem With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.